HIV sensitivity to neutralization is determined by target and virus producer cell properties

AIDS

Volumn 23, Issue 13, 2009, Pages 1659-1667

  Mann, Axel M ^a   Rusert, Peter ^a   Berlinger, Livia ^a   Kuster, Herbert ^b   Günthard, Huldrych F ^b   Trkola, Alexandra ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Entry inhibitor; Neutralization assays; Neutralizing antibodies; Passive immunization

Indexed keywords

MONOCLONAL ANTIBODY 2G12; NEUTRALIZING ANTIBODY;

ARTICLE; CELL ASSAY; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; NONHUMAN; PASSIVE IMMUNIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TARGET CELL; VIRUS ENTRY; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; CELL LINE; DRUG EVALUATION, PRECLINICAL; HIV ANTIBODIES; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; LEUKOCYTES, MONONUCLEAR; NEUTRALIZATION TESTS; VIRUS REPLICATION;

EID: 69449087173     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832e9408     Document Type: Article

References (38)

1. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312:763-767.
2. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384:184-187. (Pubitemid 26386476)
3. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384:179-183. (Pubitemid 26386475)
4. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-2864. (Pubitemid 28175522)
5. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: another look. Trends Microbiol 1999; 7:144-149.
6. Ott DE. Potential roles of cellular proteins in HIV-1. Rev Med Virol 2002; 12:359-374.
7. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928. (Pubitemid 30165271)
8. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149. (Pubitemid 36418171)
9. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
10. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622. (Pubitemid 40868301)
11. Deen KC, McDougal JS, Inacker R, Folena-Wasserman G, Arthos J, Rosenberg J, et al. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988; 331:82-84.
12. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11:533-539.
13. Barbas CFd, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 1992; 89:9339-9343.
14. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70:1100-1108. (Pubitemid 26029030)
15. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-6647. (Pubitemid 23309131)
16. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17:1757-1765. (Pubitemid 34114213)
17. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-10905. (Pubitemid 33034579)
18. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-1307. (Pubitemid 28512112)
19. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38:668-674. (Pubitemid 24113999)
20. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002; 99:395-400.
21. Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother 2003; 47:509-517. (Pubitemid 36158074)
22. Schweizer A, Rusert P, Berlinger L, Ruprecht CR, Mann A, Corthesy S, et al. CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog 2008; 4:e1000109.
23. Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, et al. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology 2004; 326:113-129. (Pubitemid 38943011)
24. Montefiori D. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. New York: John Wiley and Sons, Inc. 2004; 12.11.11-12.11.17.
25. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 1999; 73:8966-8974. (Pubitemid 29487049)
26. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73:2343-2349. (Pubitemid 29098139)
27. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, et al. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 2008; 82:1591-1599.
28. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007; 81:8793-8808.
29. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 2005; 79:8454-8469. (Pubitemid 40853547)
30. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361:212-228. (Pubitemid 46551222)
31. Thomas M, Ge Q, Lu JJ, Chen J, Klibanov AM. Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm Res 2005; 22:373-380. (Pubitemid 40558495)
32. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-10125. (Pubitemid 41098552)
33. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998; 19:346-351. (Pubitemid 28387001)
34. Louder MK, Sambor A, Chertova E, Hunte T, Barrett S, Ojong F, et al. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 2005; 339:226-238. (Pubitemid 41169790)
35. Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, Paxton WA. N-Linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 2001; 276:13433-13441. (Pubitemid 37385278)
36. Choudhry V, Zhang MY, Harris I, Sidorov IA, Vu B, Dimitrov AS, et al. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 2006; 348:1107-1115. (Pubitemid 44251203)
37. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252. (Pubitemid 39507829)
38. Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, Birx DL, et al. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008; 375:529-538.